Hydroxychavicol inhibits immune responses to mitigate cognitive dysfunction in rats

Journal of Neuroimmunology

Volumn 226, Issue 1-2, 2010, Pages 48-58

  Pandey, Anjali ^a   Bani, Sarang ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Cell surface markers; Cholinesterase; Hydroxychavicol; Lipid peroxidation; Pro inflammatory cytokines; Secretases

Indexed keywords

ACETYLCHOLINESTERASE; BETA SECRETASE; CHLOROFORM; GAMMA SECRETASE; GLUCOSE; GLUTATHIONE; HYDROXYCHAVICOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; PLANT EXTRACT; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WATER; 2-HYDROXYCHAVICOL; CHOLINE-SULFATASE; CYTOKINE; EUGENOL; GLUCOSE BLOOD LEVEL; LEUKOCYTE ANTIGEN; SECRETASE; SULFATASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD19+ B LYMPHOCYTE; CD3+ T LYMPHOCYTE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE; IMMUNOMODULATION; LIPID PEROXIDATION; LYMPHOCYTE COUNT; MALE; NEUROPROTECTION; NONHUMAN; PIPER BETEL; PIPERACEAE; PLANT LEAF; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; AVOIDANCE BEHAVIOR; BLOOD PRESSURE; BRAIN; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; WISTAR RAT;

ADMINISTRATION, ORAL; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIGENS, CD; AVOIDANCE LEARNING; BLOOD GLUCOSE; BLOOD PRESSURE; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITION DISORDERS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUGENOL; FLOW CYTOMETRY; GLUTATHIONE; LIPID PEROXIDATION; MALE; MICE; NITRIC OXIDE; RATS; RATS, WISTAR; STREPTOZOCIN; SULFATASES;

EID: 77956342174     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.05.031     Document Type: Article

References (73)

1. Alvarez X., Franco A., Fernandez-Novoa L., Cacabelos R. Blood levels of histamine, IL-1 β, and TNF-α in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol. 1996, 29:237-252.
2. Bani S., Kaul A., Khan B., Ahmad S.F., Suri K.A., Satti N.K. Imunosuppressive properties of an ethyl acetate fraction from Euphorbia royleana. J. Ethnopharmacol. 2005, 99:185-192.
3. Bani S., Kaul A., Khan B., Ahmad S.F., Suri K.A., Gupta B.D., Qazi G.N. Suppression of T lymphocyte activity by lupeol isolated from Crataeva religiosa. Phytotherapy Res. 2006, 20:279-287.
4. Bauer J., Ganter U., Strauss S., Stadtmuller G., Frommberger U., Bauer H., Volk B., Berger M. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 1992, 143:650-657.
5. Blasko I., Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003, 20:101-113.
6. Blokland A., Jolles J. Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin. Pharmacol. Biochem. Behav. 1993, 44:491-494.
7. Bonaccorso S., Lin A., Song C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Vandewoude M., Dossche A., Maes M. Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milano) 1998, 10:316-323.
8. Bruunsgaard H., Andersen-Ranberg K., Jeune B., Pedersen A.N., Skinhoj P., Pedersen B.K. A high plasma concentration of TNF-α is associated with dementia in centenarians. J. Gerontol. A Biol. Sci. Med. Sci. 1999, 54:M357-M364.
9. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 1978, 52:302-310.
10. Chang M.C., Uang B.J., Wu H.L., Lee J.J., Hahn L.J., Jeng J.H. A major phenolic compound in Piper betel leaves. Br. J. Pharmacol. 2002, 135:619-630.
11. Chopra R.N., Copra I.C., Handa K.L., Kapur L.D. Indigenous Drugs of India 1994, 371-377. BK Dhur Academic Publishers.
12. Chu Nai-Shin Effects of betel chewing on the central and autonomic nervous systems. J. Biomed. Sci. 2001, 8:229-236.
13. D'Andrea M.R., Cole G.M., Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 2004, 25:675-683.
14. Dantzer R., Bluthe R.M., Ghensi G., Cremona S., Laye S., Parnet P., Kelly K.W. Molecular basis of sickness behaviour. Ann. NY Acad. Sci. 1998, 856:132-138.
15. Das A., Dikshit M., Srivastava S.R., Srivastava U.K., Nath C. Effect of ovariectomy and estrogen supplementation on brain acetylcholinesterase activity and passive avoidance learning in rats. Can. J. Physiol. Pharm. 2002, 80(9):907-914.
16. Ellman G.L. Arch. Biochem. Biophys. 1959, 82:70-77.
17. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M.A. New and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
18. Eskandari F., Webster J.I., Sternberg E.M. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res. Ther. 2003, 5:251-265.
19. Ezio G. Cholinesterase inhibitors stabilize Alzheimer disease. Neurochem. Res. 2000, 25:1185-1190.
20. Fillit H., Ding W., Buee L. Elevated circulating TNF levels in Alzheimer's disease. Neurosci. Lett. 1991, 129:318-320.
21. Galea E., Feinstein D.L., Reis D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl Acad. Sci. USA 1992, 89:10945-10949.
22. Giacobini E. Cholinesterase inhibitors do more than inhibit cholinesterase. Alzheimer Disease: From Molecular Biology to Therapy 1996, 187-204. Birkhäuser Boston. R. Becker, E. Giacobini (Eds.).
23. Guerreiro R.J., Santana I., Brás J.M., Santiago B., Paiva A., Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegenerative Dis. 2007, 4:406-412.
24. Gunther E. The Essential Oils 1952, 160-161. D. Van Nostrand & Co, Inc, New York, 5.
25. Hanasaki Y., Ogawa S., Fukui S. The correlation between active oxygen scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med. 1994, 16:845-853.
26. Hickie I., Lloyd A. Are cytokines associated with neuropsychiatric syndrome in humans?. Int. J. Immunopharmacol. 1995, 17:677-683.
27. Hilfers M.A., Moore S.A. Amyloid-beta peptide induces cyclooxygenase-2 expression and activity in brain-derived cells. Soc. Neurosci. 1999, 25:1105. Abstr. 450.1.
28. Ho L.J., Lai J.H. Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr. Drug Metab. 2004, 5:181-192.
29. Hoozemans J.J., Veerhuis R., Janssen I., Rozemuller A.J., Eikelenboom P. Interleukin-1-beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp. Gerontol. 2001, 36:559-570.
30. Huang L.S., Wang C.K., Shew M.J., Kao L.S. Phenolic compounds of Piper betel flower as flavouring and neuronal activity modulating agents. Phenolic Compounds in Food and their Effect on Health. American Chemical Society Series 506 1992, 200-213. American Chemical Society, Washington. C.T. Ho, C.Y. Lee, M.T. Huang (Eds.).
31. Huberman M., Sredni B., Stern L., Kott E., Shalit F. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J. Neurol. Sci. 1995, 130:161-164.
32. Inestrosa N., Alvarez A., Perez C.A. Acetylcholinesterase accellerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
33. Jeng J.H., Wang Y.J., Chang W.H. Reactive oxygen species are crucial for hydroxychavicol toxicity toward KB epithelial cells. Cell. Mol. Life Sci. 2004, 61:83-96.
34. Johnstone M., Gearing A.J.H., Miller K.M. A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol. 1999, 93:182-193.
35. Kalaria R.N. Microglia and Alzheimer's disease. Curr. Opin. Hematol. 1999, 6:15-24.
36. Kaufmann I., Eisner C., Richter P., Huge V., Beyer A., Chouker A., Schelling G., Thiel M. Lymphocyte subsets and the role of TH1/TH2 balance in stressed chronic pain patients. Neuroimmunomodulation 2007, 14:272-280.
37. Krueger J.M., Fang J., Taishi P., Chen Z., Kushikata T., Gardi J. Sleep: a physiologic role for IL-1 beta and TNF-alpha. Ann. NY Acad. Sci. 1998, 856:148-159.
38. Lannert H., Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 1998, 112:199-208.
39. Li F.Q., Lu X.Z., Liang X.B., Zhou H.F., Xue B., Liu X.F., Niu D.B., Han J.S., Wang X.M. Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J. Neuroimmunol. 2004, 148:24-31.
40. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M.E. Increased plasma levels of interleukin-1, interleukin-6 and α1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 2000, 103:97-102.
41. Lombardi V.R.M., Garcia M., Rey L. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J. Neuroimmunol. 1999, 97:163-171.
42. Lombardi V.R.M., Fernandez-Novoa L., Etcheverria I. Association between APOE e4 allele and increased expression of CD95 on T cells from patients with Alzheimer's disease (AD). Methods Find. Exp. Clin. Pharmacol. 2004, 26:523-529.
43. Magari K., Miyata S., Ohkubo Y., Mutoh S. Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: effect of FK506, an inhibitor of T cell activation. Inflamm. Res. 2004, 53:469-474.
44. Mills J., Reiner P.B. Regulation of amyloid precursor protein cleavage. J. Neurochem. 1999, 72:443-460.
45. Mojard T.B., Roghani M., Hosseinzadeh S. Mefenamic acid attenuates intracerebroventricular streptozotocin-induced cognitive deficits in the rat: a behavioral analysis. IJPT 2007, 6:45-49.
46. Monosonego A., Zota V., Karni A. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 2003, 112:415-422.
47. Mori F., Lai C.C., Fusi F., Giacobini E. Cholinesterase inhibitors increase secretion of APPs in barin cortex. Neuroreport 1995, 6:633-636.
48. Nakamura Y. Regulating factors for microglial activation. Biol. Pharm. Bull. 2002, 25:945-953.
49. Organization for Economic Cooperation and Development. OECD Guidelines for Testing of Chemicals. Guideline 423, Acute Oral Toxicity - Acute Toxic Class Method, Adopted, March 22, 1996.
50. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego. 2nd ed.
51. Racchi M., Mazzucchelli M., Porello E., Lanni C., Govoni S. Acetyl cholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res. 2004, 50(4):441-451.
52. Rogers J., Lue L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39:333-340.
53. Sawada M., Kondo N., Suzumura A., Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989, 491:394-397.
54. Saxena G., Singh S.P., Pal R., Singh S., Pratap R., Chandishwar N. Gugulipid, an extract of Commiphora whighitii with lipid lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol. Biochem. Behav. 2007, 86:797-805.
55. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko K., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandervert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunisation with amyloid-beta attenuates Alzheimer's disease like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
56. Schwarz M.J., Chiang S., Müller N., Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 2001, 15:340-370.
57. Sharma M., Gupta Y.K. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 2001, 68/69:1021-1029.
58. Sharma S., Khan I.A., Ali I., Ali F., Kumar M., Kumar A., Johri R.K., Abdullah S.T., Bani S., Pandey A., Suri K.A., Gupta B.D., Satti N.K., Dutt P., Qazi G.N. Evaluation of Hydroxychavicol for its antimicrobial, antioxidant and anti-inflammatory activity for its potential uses as oral care. Antimicrob. Agents Chemother. 2009, 216-222.
59. Simmons M.L., Murphy S. Induction of nitric oxide synthase in glial cells. J. Neurochem. 1992, 59:897-905.
60. Singh V.K., Guthikonda P. Circulating cytokines in Alzheimer's disease. J. Psychiatr. Res. 1997, 31:657-660.
61. Small D.H., McLean C.A. Alzheimer's disease and amyloid beta protein; what is the role of amyloid?. J. Neurochem. 1999, 73:443-449.
62. Small D.H., Sberna G., Li Q.K. The Beta-amyloid Protein Influence Acethylcholinesterase Expression, Assembly and Glycosylation. Sixth Int. Conf. On Alzheimer's Disease and Related Disorders, Amsterdam 1998.
63. Smits H.A., Rijsmus A., Van Loon J.H., Wat J.W.Y., Verhoef J., Boven L.A. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 2002, 127:160-168.
64. Song C. The interaction between cytokines and neurotransmitters in depression and stress. Possible mechanism of antidepressant treatments. Hum. Psychopharm. Clin. 2000, 15:199-211.
65. Sternberg E.M. Interactions between the immune and neuroendocrine systems. Prog. Brain Res. 2000, 122:35-42.
66. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and α2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 1992, 66:223-230.
67. Suh Y., Chong H., Kim Y.H. Molecular physiology, biochemistry and pharmacology of Alzheimer's amyloid precursor protein (APP). Ann. N.Y. Acad. Sci. 1996, 786:169-183.
68. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of TNF-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 1999, 19:223-230.
69. Togo T., Katsuse O., Iseki E. Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. Neurol. Res. 2004, 26(5):563-566.
70. Veerendra M.H., Gupta Y.K. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. Clin. Exp. Pharmacol. Physiol. 2003, 30:336-342.
71. Vehmas A.K., Kawas C.H., Stewart W.F. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol. Aging 2003, 24:321-331.
72. Wang C.K., Hwang L.S. Effect of betel quid on catecholamine secretion from adrenal chromaffin cells. Proc. Natl Sci. Counc. Repub. China B 1997, 21:129-136.
73. Wealth of India, Volume VIII, Council of Scientific and Industrial Research 1969, 83-94.